Keyphrases
Polycystic Ovary Syndrome
100%
Gonadotropin-releasing Hormone
42%
Nafarelin
39%
Functional Ovarian Hyperandrogenism
32%
Dysregulation
26%
Ovarian Hyperandrogenism
25%
In Vitro Fertilization
23%
Luteinizing Hormone
23%
Steroidogenic
19%
17-hydroxyprogesterone (17-OHP)
18%
Embryo Transfer
18%
Bioactive
18%
Hyperandrogenism
18%
Dopamine
17%
Gonadotropins
17%
Bioactivity
17%
Obesity
17%
Androgens
17%
Androgen Secretion
17%
Infertility
16%
Estrogen
15%
Human Chorionic Gonadotropin
15%
Hyperresponsiveness
11%
Clinical Research Center
11%
Androgen Excess
11%
Androgen Levels
11%
Neuroendocrine Function
11%
Masculinization
11%
Ovarian Response
11%
Treatment Outcome
11%
Reproductive Health Outcomes
11%
Hirsutism
10%
Hyperandrogenic
10%
Intraovarian
10%
Pituitary
10%
21-Hydroxylase Deficiency (21OHD)
9%
Insulin
9%
Ovarian Stimulation
9%
Estradiol
9%
Pathophysiology
8%
Non-insulin-dependent Diabetes Mellitus (NIDDM)
8%
Human Menopausal Gonadotropin
8%
Laparotomy
8%
Anovulation
8%
Pregnancy Rate
8%
In Vitro Fertilization-embryo Transfer (IVF-ET)
8%
P450c17
8%
Breast Cancer
7%
Androstenedione
7%
Intranasal
7%
Medicine and Dentistry
Polycystic Ovary Syndrome
87%
Hyperandrogenism
63%
In Vitro Fertilisation
32%
Nafarelin
27%
Androgen
26%
Gonadorelin Agonist
22%
Embryo Transfer
22%
Follitropin
18%
Chorionic Gonadotropin
17%
Body Mass Index
17%
Androgen Release
17%
Health Outcomes
16%
Hydroxyprogesterone
15%
Steroid 17alpha Monooxygenase
15%
Spontaneous Abortion
14%
Corticotropin
14%
Breast Cancer
13%
Disease
13%
Follicle
11%
Reproductive Public Health
11%
Diethylstilbestrol
10%
Dexamethasone
10%
Luteinizing Hormone
10%
Steroid 21 Monooxygenase Deficiency
9%
Human Menopausal Gonadotropin
8%
Stillbirth
8%
Laparotomy
8%
Awareness
8%
Cesarean Section
8%
Congenital Malformation
8%
Uterine Cancer
8%
Gonadotropin
8%
Pregnancy Rate
7%
Maturity Onset Diabetes of the Young
7%
Androstenedione
7%
Urinary System
7%
Assisted Reproductive Technology
6%
Ovary Function
6%
Reproductive Endocrinology
6%
Oocyte
6%
Ovary Insufficiency
6%
Congenital Adrenal Hyperplasia
6%
Differential Diagnosis
6%
Pathophysiology
6%
Ectopic Pregnancy
6%
Medicine
6%
Clinical Study
5%
Steroid Release
5%
Secretion (Process)
5%
Insemination
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Polycystic Disease
59%
Hyperandrogenism
53%
Nafarelin
36%
Androgen
35%
Gonadorelin Agonist
32%
Luteinizing Hormone
16%
Follitropin
15%
Diethylstilbestrol
14%
Gonadotropin
14%
Hydroxyprogesterone
13%
Syndrome
13%
Corticotropin
12%
Dexamethasone
11%
Clinical Research
11%
Steroid 21 Monooxygenase Deficiency
9%
Ethinylestradiol
9%
Steroid 17alpha Monooxygenase
9%
Hirsutism
8%
Chorionic Gonadotropin
8%
Conjugated Estrogen
7%
Metoclopramide
7%
Oligomenorrhea
6%
Amenorrhea
6%
Non Insulin Dependent Diabetes Mellitus
6%
Androstenedione
6%
Congenital Adrenal Hyperplasia
6%
Dopamine Receptor Stimulating Agent
5%
Prolactin
5%
Steroid Reductase
5%
Menstruation Disorder
5%
Impaired Glucose Tolerance
5%
Virilization
5%
Delayed Puberty
5%
Dose-Response Study
5%
Dysmenorrhea
5%
Medroxyprogesterone Acetate
5%
Luteinizing Hormone Receptor
5%
Prevalence
5%
Pentraxin 3
5%
Uterus Bleeding
5%
Genital Bleeding
5%
Breast Cancer
5%
Human Menopausal Gonadotropin
5%
Ovary Insufficiency
5%
Noradrenalin
5%
Leuprorelin
5%
Route of Administration
5%
Retrospective Study
5%
Lung Disease
5%
Heart Disease
5%